

INDEX

Note: Page numbers of article titles are in **boldface** type.

- Absorptiometry, in bone mass
 measurement, dual-energy
 computed digital, 470-471
 dual-energy x-ray, 472-474
 dual-photon, 472-473
 photon, 471-475
 radiographic, 470
 single-photon, 471-473
 single x-ray, 472, 474
- Acid phosphatase, tartrate-resistant, as
 bone resorption marker, 504-506
- Alcohol consumption, osteoporotic fracture
 risk in, 448
- Alendronate, in osteoporosis, 606, 611, 619,
 624
- Alkaline phosphatase, as bone formation
 marker, 491-492
- Anabolic therapies, for osteoporosis, 556,
 623-637
 androgens, 554, 619, 632-633
 benefits of, 626
 bone remodeling and, 623-626
 fluoride, 630-632
 future, 634
 parathyroid hormone, 562-564,
 627-630
- Androgen(s), bone effects of, 552
 deficiency of, osteoporosis in, 460
 in peak bone mass attainment, 550
 insulin-like growth factor interactions
 with, 596
 replacement of, in osteoporosis, 554, 619,
 632-633
- Anorexia nervosa, bone mass in, 463
- Biochemical markers, for bone formation,
 489-501
 alkaline phosphatase, 491-492
 clinical use of, 493-497
 in therapy response evaluation,
 496-497
 osteocalcin, 492-493
 procollagen peptides, 489-490
 versus bone loss, 494-495
 versus fracture risk, 495
 for bone resorption, 503-525
 bone sialoprotein, 504, 509
 collagen amino-terminal cross-linked
 telopeptides, 504, 506-507
 collagen carboxy-terminal cross-linked
 telopeptides, 504, 506-507
 deoxypyridinoline, 504, 506-507
 hydroxylysine glycosides, 504, 507-
 508
 hydroxyproline, 504, 507
 in osteoporosis, 508-517
 bone mass measurement with, 509
 for diagnosis, 514-516
 for fracture risk assessment, 512-514
 for future bone loss prediction, 509-
 512
 for therapeutic monitoring, 516-520
 pyridinoline, 504, 506-507
 tartrate-resistant acid phosphatase,
 504-506
- Bisphosphonates, in osteoporosis, 606,
 611-614
 glucocorticoid-induced, 617-618
 in men, 619
 monitoring of, 616-617
- Body mass index, low, osteoporotic
 fracture risk in, 446-447
- Bone, density of, measurement of. See
Bone densitometry.
 formation of, biochemical markers for.
 See *Biochemical markers, for bone for-
 mation.*
 in remodeling, 457-459
 insulin-like growth factor-I effects on,
 596-598
 pain in, in vitamin D deficiency, 581
 remodeling of, biochemical markers for.
 See *Biochemical markers, for bone for-
 mation; Biochemical markers, for bone
 resorption.*

Bone (*Continued*)

- bone mass and, 457-459
 - in osteoporosis treatment, 607-608
 - parathyroid hormone in, 559-560
 - physiologic, 457-459
 - sex steroid effects on, 551-552
- resorption of, biochemical markers for.
 - See *Biochemical markers, for bone resorption.*
- in remodeling, 457-459
- prevention of, 603-622
- Bone densitometry, 469-488
 - accuracy of, 477-478
 - biochemical marker studies with, 509
 - family studies of, 528-530
 - in osteoporosis, 445-446
 - for fracture risk assessment, 445-446, 479-483
 - for phenotype definition, 533-534
 - for treatment monitoring, 616-617
 - indications for, 479-481
 - normative databases for, 479
 - precision of, 477-478
 - T scores in, 481-482
 - techniques for, photon absorptiometric, 471-475
 - quantitative ultrasonographic, 475-477
 - radiographic, 470-471
 - selection of, 483-485
 - World Health Organization criteria in, 481-482
 - Z scores in, 481-482
- Bone mass, adult, components of, 456-457
 - bone remodeling and, 457-459
 - genetic factors in. See *Genetic factors, in osteoporosis.*
 - in men, 618
 - in osteoporosis, androgen deficiency and, 460
 - calcium deficiency and, 460-461
 - estrogen deficiency and, 459-460
 - factors affecting, 456-457
 - glucocorticoid excess and, 462
 - peak bone mass acquisition and, 462-465
 - remodeling relationship to, 457-462
 - vitamin D deficiency and, 461-462
 - insulin-like growth factor-I and, 596-598
 - measurement of, 456-457. See also *Bone densitometry.*
 - peak, attainment of, sex steroids in, 549-550
 - factors affecting, 462-465
- Bone sialoprotein, as bone resorption marker, 504, 509
- C-propeptide, of collagen, as bone formation marker, 490
- Calcitonin, osteoporosis and, defects of, 538
 - treatment with, 610-611
- Calcium, homeostasis of, vitamin D in, 575-578
 - in osteoporosis, 569-578, 569-590
 - deficiency of, 460-461
 - evolutionary aspects of, 569
 - fracture risk and, 449
 - supplementation with, 609
 - intake of, in peak bone mass acquisition, 464
- Cancer, osteoporotic fracture risk in, 450-451
 - prevention of, vitamin D in, 585-587
- Cbfa1 transcription factor, in bone formation, 459
- Chromatography, in hydroxylysine glycoside measurement, 507-508
 - in hydroxypridinium derivative measurement, 506
 - in hydroxyproline measurement, 507
- Collagen, amino-terminal cross-linked telopeptides of, as bone resorption markers, 504, 506-507
 - carboxy-terminal cross-linked telopeptides of, as bone resorption markers, 504, 506-507
 - precursors of, as bone formation markers, 489-490
 - type A alpha 1, defects of, osteoporosis in, 534
- Colorimetric assays, for acid phosphatase, tartrate-resistant, 505-506
 - for hydroxyproline, 507
- Computed tomography, in bone mass measurement, 472, 475
- Cortisol excess, osteoporosis in, 462
- Cushing's syndrome, osteoporosis in, 462
- Cytokines, in bone resorption, 458, 460
 - sex steroids and, 552
- Dehydroepiandrosterone, in osteoporosis, 555-556
 - insulin-like growth factor interactions with, 596
- Deoxypridinoline, as bone resorption marker, 504, 506-507
- Diet, vitamin D in, 570
- 1,25-Dihydroxyvitamin D, actions of, 575-578
 - antiproliferative activity of, 584-587
 - in cancer prevention, 585-587
 - synthesis of, 575
- Dual-energy computed digital absorptiometry, in bone mass measurement, 470-471
- Dual-energy x-ray absorptiometry, in bone mass measurement, 456, 472-474

- Dual-photon absorptiometry, in bone mass measurement, 472-473
- Estrogen(s), bone effects of, 552
 deficiency of, bone resorption in, 459-460
 osteoporosis in, 450-451, 550-551
 peak bone mass and, 463-464
 in peak bone mass attainment, 549-550
 insulin-like growth factor interactions with, 595-596
 receptor for, defects of, osteoporosis in, 536-537
 replacement of, in osteoporosis, 553-554, 605-606, 609
 parathyroid hormone levels in, 561-562
- Etidronate, in osteoporosis, 613
- Exercise, lack of, osteoporotic fracture risk in, 450
- Falls, prevention of, in osteoporosis, 606-607
- Fluoride, in osteoporosis, 630-632
- Fractures, in osteoporosis, 439-453
 biochemical markers for, 495, 512-514
 epidemiology of, burden of, 439-440
 geographic variation in, 442-443
 hip, 440
 secular trends in, 443-444
 vertebral, 440
 wrist, 441
 risk factors for, 445-451, 479-483
- Genetic factors, in osteoporosis, 451, 464-465, 527-547
 family intergenerational studies in, 528-530
 future research on, 539-540
 gene mapping in, benefits of, 540-541
 methods for, 530-533
 results of, 534-539
 phenotype definition in, 533-534
 strength of, 528-530
 twin studies in, 528-530
- Glucocorticoids, osteoporosis due to, 462, 617-618
 treatment of, 630
- Growth factors, in bone formation, 459
- Growth hormone, in osteoporosis, 633-634
 insulin-like growth factor interactions with, 594-596
 peak bone mass and, 463-464
- Hip fractures, in osteoporosis, epidemiology of, 439-444
- Hydroxylysine glycosides, as bone resorption markers, 504, 507-508
- Hydroxyproline, as bone resorption marker, 504, 507
- 25-Hydroxyvitamin D, measurement of, 581-582
- Hyperparathyroidism, osteoporosis in, 460-462, 561
- Hypocalcemia challenge, parathyroid hormone response in, 563-564
- Hypogonadism, osteoporosis in, 551
 fracture risk in, 450-451
 treatment of, 553-556, 618-619
- Ibandronate, in osteoporosis, 612
- Immunoassays, for acid phosphatase, tartrate-resistant, 505-506
 for alkaline phosphatase, bone-specific, 491-492
 for bone sialoprotein, 508
 for hydroxypridinium derivatives, 506
 for osteocalcin, 492-493
 for procollagen peptides, 490
- Insulin-like growth factor binding proteins, in bone metabolism, 592-595
- Insulin-like growth factor-I, osteoporosis and, 591-602
 binding protein proteases, 593
 bone effects of, 596-598
 defects of, 537-538
 function of, 592-593
 gender differences in, 595
 physiology of, 592-596
 receptors for, 593
 regulation of, 593-596
 structure of, 592
 versus insulin-like growth factor II, 592-593
 peak bone mass and, 463-464
- Interleukin-6 receptor, defects of, osteoporosis in, 537
- Klinefelter's syndrome, bone mass in, 463
- Linkage disequilibrium mapping, in osteoporosis studies, 531-533
- Linkage mapping, in osteoporosis studies, 530-531
- Malnutrition, osteoporotic fracture risk in, 448-450
- Methyltestosterone, in osteoporosis, 632-633

- Nandrolone decanoate, in osteoporosis, 633
- Nutrition, in peak bone mass acquisition, 464-465
- osteoporotic fracture risk and, 448-450
- Osteoblasts, in bone remodeling, 457-459
- Osteocalcin, as bone formation marker, 492-493
- Osteoclasts, in bone remodeling, 457-459
- Osteocytes, in bone formation, 459
- Osteomalacia, in vitamin D deficiency, 578-581
- Osteoporosis, biochemical markers and, for bone formation, 489-501
- for bone resorption, 503-525
- bone densitometry in. See *Bone densitometry*.
- calcium in. See *Calcium, in osteoporosis*.
- diagnosis of, biochemical markers in, 514-516
- fall prevention in, 606-607
- fractures in. See *Fractures, in osteoporosis*.
- future bone loss prediction in, biochemical markers for, 509-512
- genetics of. See *Genetic factors, in osteoporosis*.
- glucocorticoid-induced, osteoporosis due to, 462
- treatment of, 617-618, 630
- in men, treatment of, 618-619
- insulin-like growth factors and, 463-464, 537-538, 591-602
- pathophysiology of, low bone mass in, androgen deficiency and, 460
- calcium deficiency and, 460-461
- estrogen deficiency and, 459-460
- factors affecting, 456-457
- glucocorticoid excess and, 462
- peak bone mass acquisition and, 462-465
- remodeling relationship to, 457-462
- vitamin D deficiency and, 461-462
- parathyroid hormone in, 559-567
- phenotypes of, definition of, 533-534
- prevention of, parathyroid hormone in, 629
- risk factors for, 445-451
- alcohol consumption, 448
- estrogen deficiency, 450-451
- genetic, 451
- in men, 618
- low bone mineral density, 445-446
- nutritional, 448-450
- physical inactivity, 450
- smoking, 447-448
- weight loss, 446-447
- sex steroids and, 549-558. See also specific hormones.
- treatment of, 603-622
- anabolic therapy in, 623-637
- androgens in, 554, 619, 632-633
- antiresorptive therapy in, 603-622
- bisphosphonates in, 606, 611-614, 616-619
- calcitonin in, 610-611
- calcium in, 609
- estrogen in. See *Estrogen(s), replacement of, in osteoporosis*.
- fluoride in, 630-632
- glucocorticoid-induced, 617-618, 630
- growth hormone in, 633-634
- in men, 618-619
- monitoring of, 496-497, 516-520, 616-617
- parathyroid hormone in, 562-564, 627-630
- preventive, 604-606
- remodeling and, 607-608
- selection of, 615-616
- selective estrogen receptor modulators in, 555, 606, 615
- strategies for, 606-607
- vitamin D in, 609
- vitamin D in. See *Vitamin D, in osteoporosis*.
- Osteoprotegerin ligand, in bone resorption, 458
- Pain, bone, in vitamin D deficiency, 581
- Pamidronate, in osteoporosis, 612, 616-617
- Parathyroid hormone, osteoporosis and, age-related changes in, 559-560
- circadian rhythm of secretion, 563
- controversy over, 564-565
- pathogenic effects, 560-562
- treatment with, 562-564, 627-630
- secretion of, in vitamin D deficiency, 579-580
- Phosphate, homeostasis of, vitamin D in, 575-578
- in hypocalcemia induction, parathyroid hormone response in, 563-564
- Photon absorptiometric densitometry, in bone mass measurement, 471-475
- Physical activity, lack of, osteoporotic fracture risk in, 450
- Prednisone, osteoporosis due to, 462
- Procollagen peptides, as bone formation markers, 489-490
- Progestins, in osteoporosis, 555
- Protein, dietary, osteoporotic fracture risk and, 450
- Puberty, peak bone mass acquisition in, 463-464
- Pyridinoline, as bone resorption marker, 504, 506-507

- Quantitative computed tomography, in bone mass measurement, 472, 475
- Radiographic absorptiometry, in bone mass measurement, 470
- Raloxifene, in osteoporosis, 555, 606, 615
- RANK (receptor activator of NF κ B ligand), in bone resorption, 458
- Receptor activator of NF κ B ligand, in bone resorption, 458
- Rickets, in vitamin D deficiency, 578-581
- Risedronate, in osteoporosis, 606, 611, 614
- Selective estrogen receptor modulators, in osteoporosis, 555, 606, 615
- Sex steroids. See also *Androgen(s)*; *Estrogen(s)*; *Testosterone*.
osteoporosis and, 549-558
androgen therapy, 554, 619, 632-633
dehydroepiandrosterone therapy, 555-556
estrogen therapy. See *Estrogen(s)*, *replacement of*, in osteoporosis.
in bone loss, 550-551
in peak bone mass development, 549-550
mechanisms of action in, 551-552
selective estrogen receptor modulator therapy, 555, 606, 615
- Sialoprotein, bone, for bone resorption, 504, 509
- Single-photon absorptiometry, in bone mass measurement, 471-473
- Single x-ray absorptiometry, in bone mass measurement, 472, 474
- Skin, vitamin D synthesis in, 570-574
- Smoking, osteoporotic fracture risk in, 447-448
- Somatomedin. See *Insulin-like growth factor-I*.
- Sunlight, in vitamin D synthesis, 570-574
- Sunscreens, vitamin D production and, 573
- T scores, in bone densitometry, 481-482
- Tamoxifen, in osteoporosis, 555
- Tartrate-resistant acid phosphatase, as bone resorption marker, 504-506
- Testosterone, deficiency of, osteoporosis in, 460, 551
- peak bone mass and, 463-464
- replacement of, in osteoporosis, 554, 632-633
- Tibolone, in osteoporosis, 556
- Transforming growth factor- β , defects of, osteoporosis in, 537
- Turner's syndrome, bone mass in, 463
- Ultrasonography, quantitative, in bone mass measurement, 475-477
- Vertebral fractures, in osteoporosis, epidemiology of, 439-441, 443
- Vitamin D, in cancer prevention, 585-587
in osteoporosis, 569-590
deficiency of, 461-462, 578-584
bone pain in, 581
fracture risk in, 449
measurement of, 581-582
osteomalacia in, 578-581
prevalence of, 581
rickets in, 578-581
treatment of, 582-584
evolutionary aspects of, 569-570
in calcium metabolism, 575-581
in phosphate metabolism, 575-581
metabolism of, 574-575
parathyroid hormone secretion and, 579-580
receptor defects in, 535-537
recommended intake of, 570-574
sources of, 570-574
supplementation with, 609
intake of, in peak bone mass acquisition, 464
receptor for, distribution of, 584-585
- Vitamin K, in bone health, 495
- Weight, loss of, osteoporotic fracture risk in, 446-447
- World Health Organization, bone densitometric criteria of, 481-482
- Wrist fractures, in osteoporosis, epidemiology of, 439-440, 442
- Z scores, in bone densitometry, 481-482
- Zoledronate, in osteoporosis, 612

